Ablative Solutions
- Industry
- Medical Devices
- Founded Year
- 2011
- Headquarters
- 301 Edgewater Place, Suite 100, Wakefield, MA 01880, United States
- Employee Count
- 54
Key People
- Kate Rumrill - President & CEO
- Tim Fischell - Chief Medical Officer and Co-Founder
- David Fischell - Co-Founder
- Kristine Canavan - VP, Regulatory Affairs
- Lisa Mastromattei - VP, Finance
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with successful backgrounds in the MedTech industry.
The leadership includes co-founders with prior successful ventures and a CEO with over 30 years in the MedTech and pharmaceutical industries, indicating a strong foundation for strategic execution.
- Clinical Need
-
Aspect: Very Strong
Summary: Hypertension affects over a billion people worldwide, representing a significant unmet clinical need.
Hypertension is a leading risk factor for cardiovascular diseases, and current treatments are often insufficient, highlighting the need for innovative solutions like Ablative Solutions' approach.
- Competition
-
Aspect: Somewhat crowded
Summary: The renal denervation market has multiple players, but Ablative Solutions offers a unique approach.
While the market includes several companies developing renal denervation technologies, Ablative Solutions' alcohol-mediated method may provide advantages over energy-based systems, offering a potential competitive edge.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing a novel medical device involves moderate technical challenges.
The company's approach requires precise delivery of therapeutic agents, which presents technical challenges, but the team's expertise suggests these are surmountable.
- Patent
-
Aspect: Strong
Summary: The company holds strong patents for its technology.
Patents covering the Peregrine System and related technologies protect the company's innovations, potentially deterring competitors and attracting investors.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding through multiple financing rounds.
With over $91 million raised in Series D financing, the company is well-positioned to advance its clinical programs and pursue regulatory approvals.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The company is conducting pivotal trials to seek regulatory approval.
The ongoing TARGET BP I pivotal trial is essential for demonstrating safety and efficacy, a prerequisite for regulatory approval and market entry.
Opportunity Rollup
- Odds of Success
- 3.55
- Peak Market Share
- 4.4
- Segment CAGR
- 4.0%
- Market Segment
- Cardiovascular Devices
- Market Sub Segment
- Interventional Cardiology
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.22 |
| 2 | 0.66 |
| 3 | 1.54 |
| 4 | 3.08 |
| 5 | 4.40 |
Key Takeaway
Ablative Solutions, with its experienced team and innovative approach to hypertension treatment, is well-positioned in a growing market, though it faces competition and regulatory challenges.